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Abstract Annexin B2 (AnxB2) is a novel member of the
annexin family of Ca
2?- and phospholipid-binding proteins
from Cysticercus cellulosae. To obtain highly pure AnxB2
with an easy and inexpensive puriﬁcation approach, its
cDNA was cloned into the prokaryotic expression vector
pJLA503 and the translation initiation codon was immedi-
ately under the control of the inducible bacteriophage
k promoters PR and PL. After induction by shifting tem-
perature, large amounts of non-fusion protein were pro-
duced in Escherichia coli in a soluble form. Then a novel
puriﬁcation method based on Ca
2?-dependent phosphati-
dylserine (PS)-binding activity was established, whereby
the purity of AnxB2 was increased to 98.7%. Western blot
analysis showed that recombinant AnxB2 was speciﬁcally
recognized by serum of pigs infected with cysticercosis. In
vitro test showed that, the recombinant AnxB2 had anti-
coagulant activity and platelet binding activity. The
expression, puriﬁcation, and initial characterization of
AnxB2 set an important stage for further characterization of
the protein.
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Introduction
Annexins are an evolutionary conserved multigene family
with Ca
2? and phospholipid-binding properties widely
distributed in eukaryotes [1]. Each member of this protein
family contains a conserved protein core characterized
by high alpha-helix content that includes the calcium-
and phospholipid-binding sites, and a variable N-terminal
domain that is speciﬁc in sequence and length for each
annexin. Although the structure of the protein core is
highly conserved, different annexins exhibit a wide bio-
chemical and functional diversity, e.g., membrane fusion
and exocytosis, inﬂammatory response, ion channel regu-
lation, angiogenesis and inhibition of blood coagulation,
etc. [2, 3]. Despite an abundance of experimental evidence
suggesting that annexins are associated with a plethora of
biological processes, exact physiological functions of
annexins remain to be identiﬁed.
Our group ﬁrst isolated and characterized a novel
annexin member from Cysticercus cellulosae by immuno-
logical screening designated as AnxB1 according to the
new nomenclature of annexins [3, 4]. Primary investigation
showed it can signiﬁcantly inhibit animal thrombosis in
vitro and in vivo [5, 6]. In addition, the platelet-binding
speciﬁcity of annexin B1 may make it useful to detect and
image arterial thrombi. Therefore, annexin B1 may have
the clinical potential for the treatment of vascular diseases
[7–9]. Recently, we isolated AnxB2, a novel member of the
annexin superfamily from the cDNA library of C. cellu-
losae using degenerate PCR based on conserved structure
core of annexins. Bioinformatics analysis revealed that it is
a novel annexin subfamily member which shares the
structural features of the annexin family in common. Due
to difﬁculty in obtaining native AnxB2 protein from
mammalian cells, we expressed it with pGEX5T- AnxB2
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puriﬁed by afﬁnity chromatography. A series of functional
tests suggest that GST- AnxB2 possessed the common
property of annexin family which binds acidic phospho-
lipid in the presence of calcium [10].
However, the GST fusion system has several disadvan-
tages in the production and application such as increased
immunogenicity and thrombin contamination, which will
be introduced when the GST tag is cleaved off. Thus, the
GST system is not suitable for the large-scale protein pro-
duction. For these reasons, we constructed a non-fusion-
expression system producing soluble AnxB2 in Escherichia
coli and investigated both the corresponding puriﬁcation
method and characterization of AnxB2.
Materials and methods
Chemicals, strains, and plasmids
All chemicals used for bacterial culture and protein puriﬁ-
cation were purchased from Sigma (St. Louis, MO, USA),
unless otherwise speciﬁed. The phospholipids 1, 2-dioleoyl-
SN-glycero-3-phosphocholine (phosphatidylcholine, PC)
and 1, 2-dioleoyl-SN-glycero-3-[phospho-l-serine] (phos-
phatidylserine, PS) were obtained from Avanti Polarlipids
(Germany). Chromatographic resins and DEAE-Sepharose
fast ﬂow were obtained from Amersham Biosciences
(Sweden). The mobile phase was prepared with Milli-Q
water (17.6 MX). The ﬁlter system was from Millipore
(Bedford, MA, USA).
Escherichia coli DH5a [supE44 D lac U169 (/80 lacZ
D M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1] and
BL21(DE3) [F
- lon ompTr B
- mB
-] were used as the cloning
and expression host cells, respectively. Plasmid pUC18-
AnxB2, which contained the full cDNA sequence of
AnxB2, was previously constructed and preserved in our
laboratory. The plasmid pJLA503 was preserved in our
laboratory as the expression vector for non-fusion expres-
sion of AnxB2 gene.
Plasmid construction
Plasmid DNA isolation and transformation of CaCl2-treated
E. coli cells were carried out by the procedure described
before [11]. Restriction endonucleases and T4 DNA ligase
wereusedaccordingtothedirectionsasrecommendedbythe
manufacturer (Promega).TheAnxB2 full-lengthcDNA was
obtained by PCR ampliﬁcation on the plasmid pUC18-
AnxB2 with primer 1 (forward): 50-CCAT ATGGCAA
AAAATACTCGCTCAC-30 (the NdeI site was underlined
and the additional ATG for initiation of translation in itali-
cized style) and primer 2 (reverse): 50-GCGGATC CTAT
TAGGATTCATTCAGTAGTGCGAGC-30 (the BamHI site
was underlined and the complementary sequences of stop
codonsTAAandTAGwereinitalicizedstyle).Theresulting
PCRproductwasgelpuriﬁedandclonedintopJLA503using
NdeI and BamHI restriction sites. The recombinant plasmid
pJLA503-AnxB2 was transformed into E. coli DH5a. and
the transformants were conﬁrmed by DNA sequencing
(TakaRa).
AnxB2 expression and puriﬁcation
The pJLA503-AnxB2 plasmid was transformed into E. coli
BL21 (DE3) cells. Transformants were grown in 29YTA
medium (tryptone 16 g/l, yeast extract 10 g/l, NaCl 5 g/l,
and ampicillin 100 lg/ml). The high expression clone was
obtained according to the results of SDS–PAGE analysis
and cultured in 29YTA medium overnight at 28C for
small-scale culture. The overnight culture (100 ml) was
then inoculated into 900 ml of the fresh medium described
above at 28C until the optical density (A600) reached 0.6–
0.8, and protein expression was induced by shifting the
temperature to 40C. After induction for 5 h, the cells were
separated from the culture medium by centrifugation at
8,000g for 15 min at 4C, and then the harvested cellular
pellet was resuspended in ice-cold calcium buffer (50 mM
Tris–HCl, pH 7.2, and 10 mM CaCl2). The suspension was
sonicated on ice for 1 min 9 5 to disintegrate the cells and
centrifuged at 10,000g for 20 min at 4C. The supernatant
was discarded, and the AnxB2 bound to bacterial mem-
branes was released by resuspending the pellet in EDTA
buffer (50 mM Tris–HCl, pH 7.2, and 20 mM EDTA) [12].
Shaken gently for 30 min, the cell debris were removed by
centrifugation, and the supernatant containing the solu
ble recombinant AnxB2 was stored at 4C for further
puriﬁcation.
The supernatant containing AnxB2 was dialyzed against
buffer A (20 mM Tris–HCl, pH 8.0, and 20 mM NaCl)
overnight at 4C, and then applied to a DEAE-Sepharose
fast ﬂow column (25 ml bed volume) that was previously
equilibrated with buffer A and eluted with a linear gradient
of 0–1 M NaCl in buffer A. The void volume and eluted
fractions from the chromatographic column were moni-
tored by absorbance at 280 nm. Fractions were collected
and subjected to SDS–PAGE analysis. For biological
assay, The eluted fractions containing AnxB2 were pooled
and dialyzed against buffer B (20 mM Hepes, pH 7.4,
100 mM NaCl), and stored at -20C.
SDS–PAGE, immunoblotting, and protein
determination
AnxB2 was analyzed by SDS–PAGE under reducing con-
ditions using 12% gels and the Tris–glycine system of
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123Laemmli [13]. The separated proteins were stained with
Coomassie brilliant blue R-250 or electroblotted on nitro-
cellulose for Western blotting analysis [14]. After being
blocked with 5% non-fat milk in 0.05% Tween/PBS (PBS-
T), the membrane was washed three times with PBS-T for
10 min and incubated further with a 1:100 dilution of
serum from pigs infected with cysticercosis for 1 h at 37C.
The membrane was washed and incubated with a 1:1,000
dilution of HRP- conjugated goat anti-pig IgG (sigma) as
second antibody, and revealed with DAB substrate
(Amersham). Protein concentration was determined by
modiﬁed Bradford method [15].
HPLC analysis
The homogeneity of the ﬁnal puriﬁed protein was assayed
by HPLC performed on a 300 9 7.8 mm Protein-Pak 125
column. The column was eluted with sodium phosphate
(pH 7.4) for 30 min at a ﬂow rate of 0.5 ml/min. Detection
was measured at 280 nm.
Determination of N-terminal amino acids sequence
The puriﬁed AnxB2 was subjected to SDS–PAGE under
reducing conditions and electrotransferred to polyvinyli-
dene diﬂuoride (PVDF) membranes. After the membrane
was brieﬂy stained by Coomassie Brilliant Blue, the band
of protein was cut out and subjected to the N-terminal
amino acid sequence analysis by Edman degradation
method, using an Applied Biosystem 492 Precise Micro-
protein Sequencer.
Prothrombin time and activated partial thromboplastin
time of AnxB2
Anticoagulant activity of the puriﬁed non-fusion AnxB2
was measured using the prothrombin time (PT) and acti-
vated partial thromboplastin time (aPTT) assays. Fresh
blood was gathered in polypropylene tubes contained
sodium citrate. Blood coagulation was initiated by simul-
taneous addition of calcium and 50 pM tissue factor with
GST-fusion AnxB2, GST-fusion AnxB1 and bovine serum
albumin (BSA) as control. The ﬁbrin formation was
detected by Thrombolyzer RackRotor (Behnk Elektronik,
Germany).
The platelet binding activity of AnxB2
Gel-ﬁltered human platelet rich plasma (PRP) was pre-
pared as previously described [16]. AnxB2, AnxB1 and
urokinase were diluted, respectively with PBS to six dif-
ferent concentrations (0, 100, 200, 300, 400 and 500 nM).
Flat-bottom 24-well plates were coated with 200 ll
samples at 4C 12 h, followed by washing three times with
PBS-Tween 20 buffer (140 mM NaCl, 10 mM Na2H-
PO4   12H2O, 1.5 mM KH2PO4, 0.1% Tween 20, pH 7.4).
Then the gel-ﬁltered platelets in 2.5 mM CaCl2 solution
were added at ﬁnal concentration of 2.3 9 10
5 platelets per
well. Platelet were activated with adenosine diphosphate
(ADP, 5 mM) at 37C for 60 min, followed by washing
three times with PBS-Tween 20. The bound platelets were
counted under light microscope. Nonspeciﬁc binding was
measured in presence of 5 mM EDTA.
Statistical assay
Data were expressed as the mean   SDðX   SÞ. Statistical
analysis was done using Student’s paired t-test and SNK
q-test. P\0.05 indicated a signiﬁcant difference.
Results
Non-fusion expression AnxB2 in E. coli
The entire protein-coding region of AnxB2 was cloned into
pJLA503 to create pJLA503-AnxB2 using NdeI and
BamHI restriction sites (Fig. 1). The ATG translation ini-
tiation codon is located in the NdeI site and immediately
downstream of the strong k promoters PR and PL, which
was regulated by a temperature-sensitive repressor cIts857
and induced by a temperature shift from 28 to 42C. E. coli
strain BL21 (DE3) was selected as the host strain, which
was deﬁcient in the Ion protease and lacked the ompT outer
membrane protease that degraded proteins during the
Fig. 1 Schematic representation of pJLA503-AnxB2 expression
plasmid. The arrow with lines shows AnxB2 cDNA insert cloned in
the NdeIand BamHI sites in the pJLA503 expression vector. The
black arrow shows the position of the k promoters PR and PL. The
higher part of the ﬁgure shows the nucleotide and corresponding
amino acid sequences of the open reading frame
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123process of puriﬁcation, thus proteins were more stable in
the host. The resultant translation product was a full-length
wild-type AnxB2.
To obtain enough soluble AnxB2, protein expression
was performed at 40C, instead of 42–45C to minimize
induction of heat shock protein and inactivate the repressor
cIts857 for transgene expression. Another reason is that
lower temperature induction may reduce thermal denatur-
ation of the expressed protein and subsequent formation of
inclusion bodies.
Production levels were analyzed by SDS–PAGE. It was
observed that there existed a very intensely staining protein
band with an apparent molecular mass of 38.6 kDa (Fig. 2a,
lane 2), accounting for about 39% of the total cellular
protein as indicated by scanning the protein density of the
SDS–PAGE gel. This protein species was absent in control
cells harboring the pJLA503 plasmid (Fig. 2a, lane 1). Its
identity as AnxB2 protein was conﬁrmed by immunode-
tection using a polyclonal antiserum against cysticercus
(Fig. 2b, lane 2).
Puriﬁcation of recombinant AnxB2
Based on Ca
2?-dependent phosphatidylserine (PS)-binding
activity, the reversible calcium-mediated binding ability of
AnxB2 to PS was utilized for puriﬁcation in our study.
During the procedure of puriﬁcation, 10 mM calcium and
20 mM EDTA were regarded as the optimal condition. A
single-step ion-exchange chromatography with DEAE-
Sepharose was performed for further puriﬁcation. AnxB2
was eluted at about 250 mM NaCl. Fractions corresponding
to the eluted peak were analyzed by SDS–PAGE gel.
The single protein band exhibiting a molecular mass
of 38.6 kDa was present (Fig. 2a, lane 3), which stained
intensively with antiserum against cysticercus (Fig. 2b,
lane 3). The purity of AnxB2 was also tested by HPLC
showing[98% purity as estimated from the percentage of
total peak area (Fig. 2c).
The puriﬁcation of AnxB2 based on 1 l of the culture
was summarized in Table 1. From approximately 339.7 mg
of AnxB2 present in the initial 868.8 mg of total protein
from a crude bacterial lysate, we ﬁnally isolated 39.2 mg of
pure AnxB2 accounting for 11.5% of the yield.
N-terminal amino acids sequence
To identify the recombinant protein further, The N-termi-
nal 13 amino acids residues sequence of the puriﬁed
AnxB2 was determined as Met-Ala-Lys-Asn-Thr-Arg-Ser-
Pro-Ser-Gln-Tyr-Phe-Asp in accord with the translated
sequence from AnxB2 cDNA (GenBank accession number:
AY998562).
Anticoagulant activity of recombinant AnxB2
Anticoagulant activity of the puriﬁed AnxB2 was measured
by PT and aPTT assays (Fig. 3). PT time was signiﬁcantly
prolonged by non-fusion AnxB2 at the dose of 40 lg/ml
and higher (P\0.05 vs. BSA control), similar to that of
GST-fusion AnxB2 at the same dose. The clotting time was
prolonged approximately 48 s at 120 lg/ml non-fusion
AnxB2, but AnxB1 had not this activity. In comparison
with AnxB1 and BSA controls, non-fusion AnxB2 and
GST-fusion AnxB2 had not effect in anticoagulant activity
in aPTT clotting assays. Therefore, there was some dif-
ference between the inhibition of coagulation pathways of
AnxB1 and AnxB2 by PT and aPTT assays. The antico-
agulant activities of non-fusion AnxB2 and GST-fusion
AnxB2 are also compared in Fig. 3. There was some
Fig. 2 a SDS–PAGE analysis of bacterial lysate and puriﬁed AnxB2.
b Immunoblot analysis of AnxB2 using a polyclonal antiserum
followed by HRP-conjugated secondary antibody. c HPLC analysis of
recombinant AnxB2 on a gel ﬁltration column. lane M, molecular
weight markers; lane 1, total protein of E. coli before induction
expression; lane 2, total protein of E. coli after induction by a
temperature shift from 28 to 42C; and lane 3, puriﬁed recombinant
AnxB2
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123difference between the relative activity of non-fusion
AnxB2 and GST-fusion AnxB2 in the ﬁgure, which sug-
gested that the presence of the GST carrier had a little
effect on the function.
The platelet binding activity of AnxB2
Platelet binding activity of the puriﬁed AnxB2 was mea-
sured by platelet adhesion assays (Fig. 4). Both non-fusion
AnxB2 and GST-fusion AnxB2 displayed calcium depen-
dent afﬁnity for ADP-activated platelets. The platelet
binding activity of AnxB2 was more than that of AnxB1 at
the dose of 100 nM protein concentration. The results
suggested that maybe the inhibitory effects of the AnxB2
are more potent than those of AnxB1. However, non-fusion
AnxB2 was unable to bind inactivated platelets (in present
5 mM EDTA), because the calcium ions have been che-
lated by EDTA.
Discussion
AnxB2 is a novel member of annexin family and has
common structural features of the family. AnxB2 contains
four typical annexin repeats, each repeat with ﬁve-alpha-
helices (A–E) and one type-II Ca
2? binding site [10].
Commonly, the anticoagulant properties of annexins are
associated with its calcium-dependent phospholipid-bind-
ing activity [17, 18]. In the clotting cascade reaction,
activated platelets provided a surface upon which the
coagulation factors gather to promote coagulation (e.g.,
activation of factor X by VIIIa and IXa). During the pro-
cedure of reaction, the precise components of these sur-
faces were not well known, but anionic phospholipids
constituted a major component of binding sites for these
cofactors and proteases. Usually, anionic phospholipids
Table 1 Puriﬁcation summary
Puriﬁcation Total protein (mg)
a AnxB2 (mg)
b Fraction AnxB2/total protein Yield (%)
Crude extract 868.6 339.7 0.391 100
Soluble extract 571.6 272.1 0.476 80.1
Column load sample 149.2 121.6 0.815 35.8
DEAE-Sepharose FF 39.7 39.2 0.987 11.5
a Total protein concentration was determined by Bradford method
b Recombinant AnxB2 concentration, in extracts and partially puriﬁed samples, was estimated by densitometric analyzes after SDS–PAGE
Fig. 3 Anticoagulant activity of recombinant non-fusion AnxB2 was
assayed by PT and aPTT, BSA, AnxB1 and GST-fusion AnxB2 as
control. Protein concentration of AnxB2, AnxB1 and BSA were 10,
40, 80, and 120 lg/ml. PT and aPTT were performed as described in
materials and methods. Error bars indicate the standard deviation of
three separate experiments. * P\0.05 versus BSA
Fig. 4 Platelet binding activity of recombinant non-fusion AnxB2
was measured by platelet adhesion assay, BSA, AnxB1, GST-fusion
AnxB2 and non-fusion AnxB2 (in present 5 mM EDTA) as control.
The assayed was performed as described in materials and methods.
Y-axis showed the number of platelets which were bond by the
proteins. Error bars indicate the standard deviation of three separate
experiments
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leaﬂet of the lipid bilayer membrane. Phospholipids move
from the inner to the outer leaﬂet of the lipid bilayer when
platelets were activated by some agonists. Thus, the anio-
nic phospholipids may play a key role in the blood coag-
ulation [19, 20]. Previous studies reveal that AnxB2 has
anticoagulant activity and platelet binding activity.
Therefore, AnxB2 possesses anticoagulant activity through
binding anionic phospholipids and preventing prothrom-
binase complex formation on phospholipid surfaces.
Commonly, the intrinsic pathway is deﬁned as a cascade
that utilizes only factors that are soluble in the plasma,
whereas the extrinsic pathway consists of some factors that
are insoluble in the plasma, e.g., membrane-bound factors
(factor VII). But biologic activity assay results suggested
that maybe AnxB2 inhibited the extrinsic coagulation
pathway but did not possess the endogenous anticoagulant
activity which is opposite from AnxB1. Maybe AnxB2 is a
speciﬁc antagonist of some coagulation factors [10]. We
are further investigating the interaction of AnxB2 and
special coagulation factors.
Recent studies revealed initial characterization of
AnxB2, but we still do not know what the real role of
AnxB2 is in C. cellulosae life cycle. To investigate the
biochemical and biophysical properties of AnxB2 further,
we reported here a non-fusion expression system in E. coli
and a rapid puriﬁcation method to obtain AnxB2 with high
purity and bioactivity. This system provides a convenient
source of recombinant AnxB2 for structure, function, and
pharmacological studies.
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